Biotech Funding Steady as AI Surges

The AI boom has reshaped startup funding, but biotech has not been swept away. Instead, it has held steady, with annual funding hovering between $36 billion and $40 billion. This consistency is notable given that overall venture investment hit a record in the first half of 2026, much of it going to a few generative AI giants. Biotech's share of the remaining capital has been respectable.

A significant portion of biotech funding is flowing to AI-focused companies. So far this year, more than $6 billion has gone to such startups, with Isomorphic Labs' $2.1 billion round leading the way. This suggests that investors are betting on AI to accelerate drug discovery and development, even as they remain cautious about the broader biotech sector.

The pipeline remains active, with many rounds at seed and early stage. Later-stage biotechs often go public after a Series B or C, and this year saw several early IPOs in hot areas like obesity and pain management. At least 12 funded companies have been acquired for $1 billion or more, indicating healthy exit activity. The trend of AI and biotech converging may bring more enthusiasm to the sector in the coming quarters.